摘要
目的:基于Akt/HO-1信号通路探讨芪归升降散对db/db小鼠的肾脏保护机制。方法:选取8周龄雄性自发性2型糖尿病db/db小鼠随机分为模型组、芪归升降散组,另取同源不发病db/m小鼠作为对照组,每组6只,连续灌胃9周后,检测尿微量白蛋白/肌酐比值(ACR)、6 h尿微量白蛋白(6hUTP)水平,血清肌酐(Cr)、尿素氮(BUN)、糖化血清蛋白(GSP)、过氧化氢酶(CAT)、总超氧化物歧化酶(T-SOD)、丙二醛(MDA)水平,观察肾脏病理改变,并检测肾皮质磷酸化蛋白激酶B(p-Akt)、血红素加氧酶-1(HO-1)蛋白表达。结果:与对照组比较,模型组小鼠尿ACR、6hUTP、Cr、BUN、GSP水平显著升高(P<0.01,P<0.05),肾脏病理出现肾小球系膜基质增生,肾小管上皮细胞空泡变性、纤维化,明显的炎性浸润,肾组织p-Akt、HO-1信号通路蛋白表达显著升高(P<0.05,P<0.01),T-SOD、CAT水平显著降低,MDA水平显著升高(P<0.01);与模型组比较,芪归升降散组可显著降低尿ACR、6hUTP、Cr、BUN、GSP水平(P<0.05,P<0.01),改善肾脏病理,下调肾皮质p-Akt、HO-1信号通路蛋白表达(P<0.05),升高T-SOD、CAT水平(P<0.01),降低MDA水平(P<0.01)。结论:芪归升降散可能通过调节Akt/HO-1信号通路,改善炎症与氧化应激,对肾脏起到良好保护作用。
Objective:To explort the renal protective mechanism of Qigui Shengjiang Powder(QSP)on db/db mice based on Akt/HO-1 signaling pathway.Methods:Eight-week-old male spontaneous type 2 diabetic db/db mice were randomly divided into control group and QSP group,and homologous non-diseased db/m mice were selected as the control group,6 in each group.After 9 weeks of gavage,ACR,6hUTP,Cr,BUN,GSP,CAT,T-SOD,MDA were measured,renal pathological changes were observed,and renal cortex p-Akt and HO-1 signaling pathway protein expressions were detected.Results:Compared with the control group,the model group urinary ACR,6hUTP,Cr,BUN and GSP increased(P<0.01,P<0.05),renal pathology showed glomerular mesangial matrix hyperplasia,renal tubular epithelial cell vacuolar degeneration,fibrosis,and obvious inflammation infiltration,renal tissue p-Akt and HO-1 signaling pathway protein expression increased(P<0.05,P<0.01),T-SOD,CAT decreased,MDA increased(P<0.01);Compared with the model group,QSP group reduced urine ACR,6hUTP,Cr,BUN,GSP(P<0.05,P<0.01),improved renal pathology,down-regulated renal p-Akt and HO-1 signal pathway protein expression(P<0.05),increased T-SOD,CAT(P<0.01),reduced MDA(P<0.01).Conclusion:QSP may improve inflammation and oxidative stress by regulating Akt/HO-1 signaling pathway,and play a good role in kidney protection.
作者
刘轶凡
刘媛媛
肖遥
胡洁
洑晓哲
傅强
赵进喜
LIU Yi-fan;LIU Yuan-yuan;XIAO Yao;HU Jie;FU Xiao-zhe;FU Qiang;ZHAO Jin-xi(Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Beijing University of Chinese Medicine Third Affiliated Hospital,Beijing 100029,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2022年第5期2862-2865,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.82074354)。